Phase 2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) for Initial Therapy of Chronic Lymphocytic Leukemia (DF/HCC 18-226)
This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of investigational drugs to learn whether the drugs work in treating a specific disease. "Investigational" means that the drugs are being studied. The FDA (the U.S. Food and Drug Administration) has not approved acalabrutinib for CLL, although it is FDA-approved for patients with relapsed mantle cell lymphoma.
This research study is evaluating the combination of three drugs - acalabrutinib, venetoclax, and obinutuzumab -- as a possible treatment for chronic lymphocytic leukemia (CLL).
The drugs involved in this study are:
- Acalabrutinib
- Venetoclax
- Obinutuzmab
Principal Investigator(s)
Steve Lo, MD
Contact
Mary Miller, LPN at 203-358-8879 or [email protected]
Location
Bennett Cancer Center
One Hospital Plaza
Stamford, CT 06902
Main: 203-276-2695
Stamford, CT 06902
Main: 203-276-2695